Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap | 643.64K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -12.26M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -80.00% |
Sales | 500k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -70.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -97.00% |
Recommedations | - | Quick Ratio | 0.16 | Shares Outstanding | 781.09K | 52W Low Chg | 50.00% |
Insider Own | - | ROA | -4.22% | Shares Float | - | Beta | 22.55 |
Inst Own | - | ROE | -125.15% | Shares Shorted/Prior | -/- | Price | 0.00030 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 3,504 | Target Price | - |
Oper. Margin | 45.31% | Earnings Date | - | Volume | 1,000 | Change | 0.00% |
About MABCURE INC
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.